Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947130003> ?p ?o ?g. }
- W2947130003 abstract "Sepsis still represents a major health issue, with persistent high morbidity and mortality rates. Cardiovascular dysfunction occurs frequently during sepsis. Adrenomedullin has been identified as a key mediator in vascular tone regulation. A non-neutralizing anti-adrenomedullin antibody, Adrecizumab, may improve haemodynamic dysfunction during caecal ligation and puncture-induced septic shock in a murine model. Our objective was to determine the role of Adrecizumab on haemodynamics in a rat model of sepsis.For the induction of sepsis, caecal ligation and puncture were performed in Wistar male rats. Single blinded administration of Adrecizumab (2 mg/kg) or placebo was injected i.v. 24 h after the surgery, and norepinephrine was infused as the standard of care. There were > 7 animals per group. Invasive blood pressure and cardiac function (by echocardiography) were assessed until 3 h after Adrecizumab injection.A single therapeutic injection of Adrecizumab in septic rats induced rapid haemodynamic benefits with an increase in systolic blood pressure in septic-Adrecizumab rats versus untreated-septic rats (p = 0.049). The shortening fraction did not differ between the untreated-septic and septic-Adrecizumab groups. However, cardiac output increased during the 3 h after a single dose of Adrecizumab compared to untreated septic rats (p = 0.006). A single dose of Adrecizumab resulted in similar haemodynamics to the continuous administration of norepinephrine. Three hours after a single injection of Adrecizumab, there was no change in the inflammatory phenotype (TNFα, IL-10) in the hearts of the septic rats. By contrast, 3 h after a single Adrecizumab injection, free-radical production decreased in the hearts of septic-Adrecizumab vs untreated septic rats (p < 0.05).In a rat model of sepsis, a single therapeutic injection of Adrecizumab rapidly restored haemodynamic parameters and blunted myocardial oxidative stress. Currently, a proof-of-concept and dose-finding phase II trial (Adrenoss-2) is ongoing in patients with septic shock and elevated concentrations of circulating bio-adrenomedullin." @default.
- W2947130003 created "2019-06-07" @default.
- W2947130003 creator A5006382948 @default.
- W2947130003 creator A5016291358 @default.
- W2947130003 creator A5017917935 @default.
- W2947130003 creator A5025445136 @default.
- W2947130003 creator A5053396923 @default.
- W2947130003 creator A5059904200 @default.
- W2947130003 creator A5065857863 @default.
- W2947130003 creator A5078485761 @default.
- W2947130003 creator A5079600079 @default.
- W2947130003 creator A5084411330 @default.
- W2947130003 date "2019-05-15" @default.
- W2947130003 modified "2023-10-14" @default.
- W2947130003 title "Adrecizumab, a non-neutralizing anti-adrenomedullin antibody, improves haemodynamics and attenuates myocardial oxidative stress in septic rats" @default.
- W2947130003 cites W1985266427 @default.
- W2947130003 cites W2033692310 @default.
- W2947130003 cites W2035192492 @default.
- W2947130003 cites W2036983784 @default.
- W2947130003 cites W2048703304 @default.
- W2947130003 cites W2051810155 @default.
- W2947130003 cites W2066837470 @default.
- W2947130003 cites W2077603081 @default.
- W2947130003 cites W2092419989 @default.
- W2947130003 cites W2104583114 @default.
- W2947130003 cites W2106607054 @default.
- W2947130003 cites W2109308366 @default.
- W2947130003 cites W2110920739 @default.
- W2947130003 cites W2122628753 @default.
- W2947130003 cites W2123083118 @default.
- W2947130003 cites W2133885267 @default.
- W2947130003 cites W2134283594 @default.
- W2947130003 cites W2141678261 @default.
- W2947130003 cites W2155301630 @default.
- W2947130003 cites W2164990391 @default.
- W2947130003 cites W2280404143 @default.
- W2947130003 cites W2296055557 @default.
- W2947130003 cites W2335635083 @default.
- W2947130003 cites W2344558888 @default.
- W2947130003 cites W2544397718 @default.
- W2947130003 cites W2606664140 @default.
- W2947130003 cites W2762225173 @default.
- W2947130003 cites W2782852727 @default.
- W2947130003 cites W2783073608 @default.
- W2947130003 cites W2791367003 @default.
- W2947130003 cites W2804699844 @default.
- W2947130003 doi "https://doi.org/10.1186/s40635-019-0255-0" @default.
- W2947130003 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6520420" @default.
- W2947130003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31093784" @default.
- W2947130003 hasPublicationYear "2019" @default.
- W2947130003 type Work @default.
- W2947130003 sameAs 2947130003 @default.
- W2947130003 citedByCount "24" @default.
- W2947130003 countsByYear W29471300032020 @default.
- W2947130003 countsByYear W29471300032021 @default.
- W2947130003 countsByYear W29471300032022 @default.
- W2947130003 countsByYear W29471300032023 @default.
- W2947130003 crossrefType "journal-article" @default.
- W2947130003 hasAuthorship W2947130003A5006382948 @default.
- W2947130003 hasAuthorship W2947130003A5016291358 @default.
- W2947130003 hasAuthorship W2947130003A5017917935 @default.
- W2947130003 hasAuthorship W2947130003A5025445136 @default.
- W2947130003 hasAuthorship W2947130003A5053396923 @default.
- W2947130003 hasAuthorship W2947130003A5059904200 @default.
- W2947130003 hasAuthorship W2947130003A5065857863 @default.
- W2947130003 hasAuthorship W2947130003A5078485761 @default.
- W2947130003 hasAuthorship W2947130003A5079600079 @default.
- W2947130003 hasAuthorship W2947130003A5084411330 @default.
- W2947130003 hasBestOaLocation W29471300031 @default.
- W2947130003 hasConcept C126322002 @default.
- W2947130003 hasConcept C139940330 @default.
- W2947130003 hasConcept C170493617 @default.
- W2947130003 hasConcept C178853913 @default.
- W2947130003 hasConcept C2776452961 @default.
- W2947130003 hasConcept C2777152744 @default.
- W2947130003 hasConcept C2777628635 @default.
- W2947130003 hasConcept C2777953023 @default.
- W2947130003 hasConcept C2778384902 @default.
- W2947130003 hasConcept C2778514916 @default.
- W2947130003 hasConcept C2781300812 @default.
- W2947130003 hasConcept C42219234 @default.
- W2947130003 hasConcept C513476851 @default.
- W2947130003 hasConcept C71924100 @default.
- W2947130003 hasConcept C84393581 @default.
- W2947130003 hasConceptScore W2947130003C126322002 @default.
- W2947130003 hasConceptScore W2947130003C139940330 @default.
- W2947130003 hasConceptScore W2947130003C170493617 @default.
- W2947130003 hasConceptScore W2947130003C178853913 @default.
- W2947130003 hasConceptScore W2947130003C2776452961 @default.
- W2947130003 hasConceptScore W2947130003C2777152744 @default.
- W2947130003 hasConceptScore W2947130003C2777628635 @default.
- W2947130003 hasConceptScore W2947130003C2777953023 @default.
- W2947130003 hasConceptScore W2947130003C2778384902 @default.
- W2947130003 hasConceptScore W2947130003C2778514916 @default.
- W2947130003 hasConceptScore W2947130003C2781300812 @default.
- W2947130003 hasConceptScore W2947130003C42219234 @default.
- W2947130003 hasConceptScore W2947130003C513476851 @default.
- W2947130003 hasConceptScore W2947130003C71924100 @default.
- W2947130003 hasConceptScore W2947130003C84393581 @default.
- W2947130003 hasIssue "1" @default.